The company recently launched a clinical trial of its CLAAS implant. The implant features foam-based architecture designed to help simplify left atrial appendage occlusion procedures and create a uniform seal.
Sprig Equity led the financing round, according to a June 5 Conformal Medical news release.
“Conformal Medical is committed to bringing the innovative CLAAS System to the large and rapidly growing LAAO market in the United States,” Conformal CEO James Reinstein said in the release. “The series D funding provides us the resources to complete enrollment in the Conform trial, drive iterative development projects, and broaden the clinical experience of the CLAAS system in expanded geographies.”
